Breast cancer survivors receiving endocrine (hormonal) therapy (aromatase inhibitors) are at high risk for cancer treatment-induced bone loss and osteoporosis due to estrogen depletion.
Female breast cancer survivors aged 40-60 years.
Histologically confirmed stage I-III breast cancer.
Currently receiving hormonal therapy (aromatase inhibitors) for at least 3 months.
At risk of osteoporosis or with low bone mineral density (BMD) defined by T-score ≤ -1.0 at lumbar spine or hip.
Metastatic (stage IV) or recurrent breast cancer.
History of osteoporotic fractures in the past 12 months.
Severe cardiovascular, respiratory, or musculoskeletal conditions that contraindicate exercise.
Uncontrolled hypertension, diabetes, or thyroid disorders.